Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study

Blood (2018) 132 (Supplement 1): 1960.

https://doi.org/10.1182/blood-2018-99-112155

Published: 2018

Journal Articles

Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients with Impaired Renal Function: Efficacy Analysis of PrE1003, a Precog Study

Joseph Mikhael, MD, Judi Manola, Sagar Lonial, MD FACP, Brendan M Weiss, MD, Kurt Oettel, MD, Suzanne R. Hayman, MD, Abraham S. Kanate, MD, S. Vincent Rajkumar, MD

Blood (2016) 128 (22): 5712.

https://doi.org/10.1182/blood.V128.22.5712.5712

Published: 2016

Journal Articles

Cost and Efficacy of Upfront Plerixafor Versus a “Just-in-Time” (JIT) Approach in Hematopoietic Progenitor Cell (HPC) Mobilization

Lauren Westfall Veltri, MD, Aaron Cumpston, PharmD, Alexandra Shillingburg, PharmD, Christopher Lipinski, Sijin Wen, PhD, Sonia Leadmon, Kathy Watkins, MT, Lab Technician, Michael David Craig, MD, Mehdi Hamadani, MD, Abraham S. Kanate, MD

Blood (2014) 124 (21): 1127.

https://doi.org/10.1182/blood.V124.21.1127.1127

Published: 2014

Journal Articles

In Vivo T-Cell Depletion Does Not Improve Rates of Graft-Versus-Host Disease and Transplantation Outcomes In Patients Undergoing Peripheral Blood Hematopoietic Cell Transplant.

Abraham S Kanate, MD, Salman Osman, MD, Aaron Cumpston, PharmD, Gerry Hobbs, PhD, Sonia Leadmon, BS, Pamela Bunner, BS, Laura Gibson, PhD, William Tse, MD, Jame Abraham, MD, FACP, Scot Remick, MD, FACP, Michael Craig, MD, Sayed Mehdi Hamadani, MD

Blood (2010) 116 (21): 4536.

https://doi.org/10.1182/blood.V116.21.4536.4536

Published: 2010

Journal Articles

Higher Infused CD34+ Cell Dose Improves Survival In Patients Undergoing In Vivo T-Cell Depleted, but Not T-Cell Replete Peripheral Blood Hematopoietic Cell Transplant

Abraham S Kanate, MD, Salman Osman, MD, Aaron Cumpston, PharmD, Gerry Hobbs, PhD, Sonia Leadmon, BS, Pamela Bunner, BS, Kathy Watkins, MT, Laura Gibson, PhD, William Tse, MD, Jame Abraham, MD, FACP, Scot Remick, MD, FACP, Michael Craig, MD, Sayed Mehdi Hamadani, MD

Blood (2010) 116 (21): 1272.

https://doi.org/10.1182/blood.V116.21.1272.1272

Published: 2010

Journal Articles

Effect of T-Cell Dose On Outcomes After Peripheral Blood Allogeneic Hematopoietic Cell Transplantation in Hematological Malignancies.

Abraham S Kanate, MD, Farhad Khimani, MD, Aaron Cumpston, PharmD, Kathy Watkins, BS, Sonia Leadmon, BS, Michael D Craig, MD

Blood (2009) 114 (22): 1171.

https://doi.org/10.1182/blood.V114.22.1171.1171

Published: 2009

NARROW

Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study

Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients with Impaired Renal Function: Efficacy Analysis of PrE1003, a Precog Study

Cost and Efficacy of Upfront Plerixafor Versus a “Just-in-Time” (JIT) Approach in Hematopoietic Progenitor Cell (HPC) Mobilization

In Vivo T-Cell Depletion Does Not Improve Rates of Graft-Versus-Host Disease and Transplantation Outcomes In Patients Undergoing Peripheral Blood Hematopoietic Cell Transplant.

Higher Infused CD34+ Cell Dose Improves Survival In Patients Undergoing In Vivo T-Cell Depleted, but Not T-Cell Replete Peripheral Blood Hematopoietic Cell Transplant

Effect of T-Cell Dose On Outcomes After Peripheral Blood Allogeneic Hematopoietic Cell Transplantation in Hematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study

Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients with Impaired Renal Function: Efficacy Analysis of PrE1003, a Precog Study

Cost and Efficacy of Upfront Plerixafor Versus a “Just-in-Time” (JIT) Approach in Hematopoietic Progenitor Cell (HPC) Mobilization

In Vivo T-Cell Depletion Does Not Improve Rates of Graft-Versus-Host Disease and Transplantation Outcomes In Patients Undergoing Peripheral Blood Hematopoietic Cell Transplant.

Higher Infused CD34+ Cell Dose Improves Survival In Patients Undergoing In Vivo T-Cell Depleted, but Not T-Cell Replete Peripheral Blood Hematopoietic Cell Transplant

Effect of T-Cell Dose On Outcomes After Peripheral Blood Allogeneic Hematopoietic Cell Transplantation in Hematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only